PharmaShots | Incisive News in 3 Shots

Subscribe Now

Ophthalmic

Samsung Bioepis' Byooviz (biosimilar- ranibizumab) Receives EC's Approval for the Treatment of Ophthalmic in EU

Samsung Bioepis' Byooviz (biosimilar- ranibizumab) Receives EC's Approval for the Treatment of Ophthalmic in EU

August 23, 2021

Kala Pharmaceuticals' Eysuvis (loteprednol etabonate ophthalmic suspension) Receives US FDA's Approval for Dry Eye Disease

Kala Pharmaceuticals' Eysuvis (loteprednol etabonate ophthalmic suspension) Receives US FDA's Approval for Dry Eye Disease

October 27, 2020

Regeneron Collaborates with Alnylam to Discover- Develop and Commercialize RNAi Therapeutics for Ophthalmic and CNS Disorders

Regeneron Collaborates with Alnylam to Discover- Develop and Commercialize RNAi Therapeutics for Ophthalmic and CNS Disorders

April 9, 2019

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us